Comprehensive Dermatologic Drug Therapy

Comprehensive Dermatologic Drug Therapy

4th Edition - December 14, 2019

Write a review

  • Authors: Stephen Wolverton, Jashin Wu
  • Hardcover ISBN: 9780323612111
  • eBook ISBN: 9780323612128

Purchase options

Institutional Subscription

Free Global Shipping
No minimum order


Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you’re likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You’ll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.

Table of Contents

  • Part I: Introduction

    1 Basic Principles of Pharmacology

    2 Principles for Maximizing the Safety of Dermatologic Drug Therapy

    3 Polymorphisms: Why Individual Drug Responses Vary

    4 Adherence to Drug Therapy

    5 Medical Decision Making

    Part II: Important Drug Regulatory Issues

    6 The FDA Drug Approval Process

    7 Pharmacovigilance: Verifying that Drugs Remain Safe

    8 Drugs Taken Off the Market: Important Lessons Learned

    Part III: Systemic Drugs for Infectious Diseases

    9 Systemic Antibacterial Agents

    10 Systemic Antifungal Agents

    11 Systemic Antiviral Agents

    12 Systemic Antiparasitic Agents

    Part IV: Systemic Immunomodulatory Drugs

    13 Systemic Corticosteroids

    14 Methotrexate

    15 Azathioprine

    16 Mycophenolates

    17 Cyclosporine

    18 Phosphodiesterase-4 and Janus Kinase Inhibitors

    19 Cytotoxic Agents

    20 Dapsone

    21 Antimalarial Agents

    22 Systemic Retinoids

    Part V: Drugs Used in Conjunction with UV or Visible Light

    23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities

    24 Extracorporeal Photochemotherapy (Photopheresis)

    25 Photodynamic Therapy

    Part VI: Biologic Therapeutics

    26 Tumor Necrosis Factor Inhibitors

    27 Interleukin 12/23 Inhibitors

    28 Interleukin 17 Inhibitors

    29 Interleukin 23 Inhibitors

    30 Rituximab

    31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

    Part VII: Miscellaneous Systemic Drugs

    32 Antihistamines

    33 Vasoactive and Antiplatelet Agents

    34 Antiandrogens and Androgen Inhibitors

    35 Psychotropic Agents

    36 Intravenous Immunoglobulin Therapy

    37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events

    38 Hedgehog Pathway Inhibitors

    39 Drugs for the Skinternist

    40 Miscellaneous Systemic Drugs

    Part VIII: Topical Drugs for Infectious Diseases

    41 Topical Antibacterial Agents

    42 Topical Antifungal Agents

    43 Topical and Intralesional Antiviral Agents

    44 Topical Antiparasitic Agents

    Part IX: Topical Immunomodulatory Drugs

    45 Topical Corticosteroids

    46 Topical Retinoids

    47 Topical and Intralesional Chemotherapeutic Agents

    48 Topical Calcineurin Inhibitors

    49 Topical Vitamin D3

    Part X: Miscellaneous Topical Drugs

    50 Sunscreens

    51 Therapeutic Shampoos

    52 α-Hydroxy Acids

    53 Chemical Peels

    54 Products for the Care of Chronic Wounds

    55 Agents Used for Treatment of Hyperkeratosis

    56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents

    57 Miscellaneous Topical Agents

    Part XI: Injectable and Mucosal Routes of Drug Administration

    58 Local Anesthetics

    59 Injectable Dermal and Subcutaneous Fillers

    60 Botulinum Toxin Injections

    61 Oral Mucosal Therapeutics

    Part XII: Major Adverse Effects From Systemic Drugs

    62 Hepatotoxicity of Dermatologic Drug Therapy

    63 Hematologic Toxicity of Drug Therapy

    64 Drug-induced Malignancy

    65 Dermatologic Drugs During Pregnancy and Lactation

    66 Drug Interactions

    67 Cutaneous Drug Reactions With Systemic Features

    Part XIII: Special Pharmacology and Therapeutics Topics

    68 Informed Consent and Risk Management

    69 Compounding in Dermatology

    70 Dermatologic Drug Therapy in Children

    Appendix I Core Questions for Understanding Systemic Dermatologic Drugs

    Appendix II The Most Potentially Serious Drug Interactions

Product details

  • No. of pages: 858
  • Language: English
  • Copyright: © Elsevier 2020
  • Published: December 14, 2019
  • Imprint: Elsevier
  • Hardcover ISBN: 9780323612111
  • eBook ISBN: 9780323612128

About the Authors

Stephen Wolverton

Affiliations and Expertise

Professor of Clinical Dermatology Vice Chair of Clinical Affairs

Jashin Wu

Affiliations and Expertise

Founder and Course Director, San Diego Dermatology Symposium; Founder and CEO Dermatology Research and Education Foundation Irvine, California, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Comprehensive Dermatologic Drug Therapy"